Dr. Shaker Dakhil Publishes in Journal of Clinical Oncology for Melanoma Trial

Dr. Shaker Dakhil has been recognized as an author in a trial of patients with newly diagnosed melanoma in the Journal of Clinical Oncology, one of the most respected publications in the field (the article is available in its entirety below). These trials will provide further guidance to help negotiate the complex choices that are available for therapy of adjuvant high-risk melanoma.  The Cancer Center of Kansas is so proud to be one of only 46 cancer research programs in the nation currently funded by the National Cancer Institute Community Oncology Research Program (NCORP). NCORP is a national network of cancer care investigators, providers, academia, and other organizations that care for diverse populations in health systems and conduct high quality trials that are aimed to better understand oncology through studies that work to prevent and/ or care for cancer.


For more information on the Journal of Clinical Oncology please visit:

  • Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma